Epigenomics AG Company Overview and Details

Author

Reads 8.1K

Personalized medicine in the age of genomics
Credit: pexels.com, Personalized medicine in the age of genomics

Epigenomics AG is a German biotechnology company founded in 1996 by Thomas Stiefelhagen and Thomas Taft.

The company is headquartered in Berlin, Germany, and has a second site in Seattle, Washington, USA.

Epigenomics AG focuses on the development and commercialization of diagnostic solutions for the detection of cancer biomarkers.

Their products are designed to help doctors diagnose and treat cancer more effectively, particularly in the early stages.

Recommended read: Sap Ag Company

Expand your knowledge: Blis Technologies

Company Information

Epigenomics AG is a leading company in the field of liquid biopsy and non-invasive cancer diagnostics. It was founded in 2000 in Berlin, Germany.

The company's headquarters is located in Berlin, Germany, where the team of experts works on developing innovative diagnostic solutions. Epigenomics has a presence in the US, with its subsidiary Epigenomics US, Inc. based in Cambridge, Massachusetts.

Epigenomics has a strong focus on research and development, with a team of scientists working on identifying and validating novel biomarkers for cancer and other diseases.

Consider reading: Investitionsbank Berlin

SIC Code

Credit: youtube.com, Business & Office Tips : How to Find Company SIC Codes

The SIC code is a crucial piece of information for any company. It's a classification system used by the US government to categorize businesses by industry.

The SIC code for Epigenomics AG is 87, 873.

This code tells us that Epigenomics AG operates in the scientific and technical services industry.

A fresh viewpoint: Deutsche Bank Ag Swift Code

Kontaktdaten

Our company's contact information is easily accessible, and we're happy to share it with you. You can reach us by phone at +49 123 456 789.

We're located at Münchner Str. 123, 80802 München, Germany.

Our email address is [[email protected]](mailto:[email protected]).

You can also visit our website at company.de for more information.

Financials

Epigenomics AG's financials are a crucial aspect of its business. The company's stock price, or Aktienkurs, has fluctuated significantly over time, with a current price of 1,0785 EUR.

The 52-week high for Epigenomics AG's stock price was 4,0000 EUR, a substantial increase from its current value. This indicates that the company's stock has experienced a significant surge in value over the past year.

Here are the key financial metrics for Epigenomics AG:

Stock Price

Credit: youtube.com, Stock Multiples: How to Tell When a Stock is Cheap/Expensive

The stock price of Epigenomics is currently at 1,0785 EUR, which is the price from the previous day.

The 52-week high for Epigenomics stock is a significant 4,0000 EUR, a number that highlights the potential for substantial growth.

In contrast, the 52-week low is a relatively low 0,5000 EUR, showing that the stock has experienced some volatility in the past year.

Here's a quick rundown of the current stock price and its historical highs and lows:

Alibaba Acquires German Diagnostics Company for $12M

The acquisition is actually by New Day Diagnostics, a US-based company, not Alibaba. New Day Diagnostics has agreed to acquire Epigenomics, a German molecular diagnostics company, for a total consideration of up to $12m.

The deal follows New Day's recent merger with EDP Biotech, a medical device company focused on immunodiagnostic tests. This acquisition adds to their portfolio in the cancer diagnostics space.

Epigenomics will receive $1.8m in cash payments, with the potential for up to $8m more contingent on achieving certain milestones related to Epi proColon and Epi proColon Next-Gen.

New Day Diagnostics will pay Epigenomics a 3% shareholding in the company, valued at $2.25m. This shareholding will remain until October 2043.

The acquisition brings unique biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a non-invasive CRC screening test.

Take a look at this: New World First Bus

Management

Credit: youtube.com, Encode Ideas, L.P. Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) July 28, 2020

Epigenomics AG has a strong leadership team in place. Michael Wandell is the Senior Vice President, Clinical, Regulatory and Quality of the company. His expertise is crucial in driving the company's clinical, regulatory, and quality initiatives forward.

The company's management team is well-equipped to navigate the complex landscape of genetic testing and diagnostics. Michael Wandell brings a wealth of experience to his role, ensuring that Epigenomics AG operates with the highest level of quality and regulatory compliance.

How Many Employees?

Epigenomics AG is a company with a relatively small team. 22 people are employed at Epigenomics AG.

Senior Vice President, Clinical, Regulatory and Quality

Michael Wandell is the Senior Vice President, Clinical, Regulatory and Quality of Epigenomics AG.

Michael Wandell's role involves overseeing the clinical, regulatory, and quality aspects of Epigenomics AG.

Community and Discussion

The Epigenomics AG community is actively engaged in discussions about the company's prospects. The wallstreetONLINE Community has shared their thoughts on Epigenomics, and it's worth taking a look.

A recent discussion on wallstreetONLINE started with the question "Was ist Ihre Meinung?" or "What's your opinion?" which sparked a lively debate among community members.

Data and Details

Credit: youtube.com, Bradley Bernstein: Visualizing Epigenomics Data

Epigenomics AG is a company based in Germany, specifically in the biotechnology sector.

The company's full name is Epigenomics AG, with the short name Epigenomics and the registered name Epigenomics AG Registered Shs After capital reduction.

The stock type is a stammaktie, which is a type of common stock.

The stock has a WKN (Wertpapier-Kennzahl) of A37FT4 and an ISIN (International Securities Identification Number) of DE000A37FT41.

Epigenomics AG has a market capitalization of 945,35 thousand EUR and a total number of shares of 876,95 thousand.

Questions and Answers

What do you want to know about Epigenomics AG? Let's get started!

The company is based in Germany, with a focus on developing diagnostic solutions for cancer and other diseases.

Epigenomics AG was founded in 1998, and it's been working on improving cancer diagnostics ever since.

Their flagship product is Epi proLung, a blood-based test for lung cancer detection.

Epi proLung is a liquid biopsy that can detect lung cancer biomarkers in blood samples.

Credit: youtube.com, Short talks: Epigenomics Gene Regulation

This test has shown high sensitivity and specificity in clinical studies.

Epigenomics AG has also developed other products, including Epi proColon, a blood test for colorectal cancer screening.

Their technology is based on methylation-specific PCR (MSP) and pyrosequencing.

Epigenomics AG has partnerships with other companies to further develop and commercialize their products.

These partnerships have helped expand their reach and improve their diagnostic solutions.

The company has also received regulatory approvals for their products in various countries.

Regulatory approvals are a big step forward for any biotech company!

Wallace Brekke

Junior Assigning Editor

Wallace Brekke is a seasoned Assigning Editor with a keen eye for detail and a passion for storytelling. With a keen interest in finance and economics, Brekke has honed their skills in assigning and editing articles on a range of topics, including market trends and commodity prices. Brekke's expertise spans a variety of categories, including gold prices and historical commodity prices.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.